IL6 and diffuse large B-cell lymphoma: Thus, the virtual NHL population satisfactorily captures and predicts clinical data on both the safety surrogate biomarker (IL6 levels) and efficacy (tumor B-cell killing) for DLBCL and is suitable for predicting the results for mosunetuzumab in a similar patient population.